Submit Deal

CELGENE CORPORATION

Summary

Celgene is a global biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases.

Deals Overview

Total Deals7

Valued Deals6

Total Value£99,062M

Avg. Deal Size£16,510M

Market Context

Subsidiaries

OTEZLA

1 transaction

Senior Management

Peter N. Kellogg
Chief Corporate Strategy Officer & Executive Vice President
Jonathan Biller
General Counsel

Deals (7)

Service Providers

Relationships

Portfolio

Team

Sort

United States

Biotechnology

PrivateAcquisition

target

Impact Biomedicines

bidder

Celgene Corporation

£811m

10 dealmakers

United States

Biotechnology

PublicAcquisitionMajority

target

Juno Therapeutics

bidder

Celgene Corporation

£5,862m

60 dealmakers

United States

Biotechnology

AcquisitionPublic

target

Receptos Inc.

bidder

Celgene Corporation

£4,639m

4 dealmakers

United States

Biotechnology

AcquisitionPublicMajorityDomestic

target

Celgene Corporation

bidder

Bristol Myers Squibb Company

£70,659m

83 dealmakers

United States

Pharmaceuticals

MajorityAcquisitionPrivateDomestic

target

OTEZLA

bidder

Amgen

£10,900m

46 dealmakers

United States

Biotechnology

AcquisitionMajorityPrivatePrivate Equity

target

Atxco

bidder

Blade Therapeutics

value n/a

7 dealmakers

United States

Medical Services

MajorityPrivateAcquisitionDomesticPrivate Equity

target

GRAIL

bidder

Illumina

£6,190m

107 dealmakers

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.